Company Overview and News

21
Ideal Employer Survey: Which Continent Values Oil, Gas Safety Most?

2h rigzone
Africa has valued an oil and gas company’s commitment to health and safety (H&S) more than any other continent for the second year in a row, Rigzone’s 2018 Ideal Employer Survey (IES) has revealed.
RDS.B RDS.A RYDBF RDSB RDSA RYDAF

21
Shell sells US$1.3b of O&G assets in Norway, Malaysia

9h theedgemarkets
LONDON/OSLO (June 20): Royal Dutch Shell announced the sale on Wednesday of oil and gas assets in Norway and Malaysia for over US$1.3 billion, bringing it closer to a target of US$30 billion in disposals by year-end.
BRGXF BG BRGYY RDS.B RDS.A RYDBF RDSB RDSA RYDAF

21
Shell sells US$1.3bil of oil and gas assets in Malaysia, Norway

13h thestar.com.my
Earlier, Shell announced the completion of the sale of a 15 percent stake in Malaysia LNG (MLNG) Tiga to the Sarawak State Financial Secretary for US$750 million.
BRGXF BG BRGYY RDS.B RDS.A RYDBF RDSB RDSA RYDAF

22
Vitol Launches Viva Energy Float, Australia's Biggest In 4 Years

16h rigzone
MELBOURNE, June 20 (Reuters) - Global energy trader Vitol kicked off the planned A$5 billion ($3.7 billion) float of its Australian refinery and fuel supply network Viva Energy on Wednesday, in what would be the country's biggest initial public offering in four years.
CTX RDS.B RDS.A CTXAY CTXAF RYDBF TRI RDSB RDSA RYDAF

21
[Press] Shell to Sell Draugen and Gjøa Interests to OKEA AS

16h oilvoice
Royal Dutch Shell plc, through its affiliate A/S Norske Shell, has reached an agreement with OKEA AS to sell its entire 44.56% interest in Draugen and 12.00% interest in Gjøa in Norway for $556* million (NOK 4,520 million).
RDS.B RDS.A RYDBF RDSB RDSA RYDAF

21
[Press] Shell to sell Draugen and Gjøa interests to OKEA AS

16h oilvoice
Royal Dutch Shell plc, through its affiliate A/S Norske Shell, has reached an agreement with OKEA AS to sell its entire 44.56% interest in Draugen and 12.00% interest in Gjøa in Norway for $556* million (NOK 4,520 million).
RDS.B RDS.A RYDBF RDSB RDSA RYDAF

21
[Press] Shell Completes Malaysia LNG Tiga Equity Sale

16h oilvoice
Shell Gas Holdings (Malaysia) Limited, a subsidiary of Royal Dutch Shell plc, announced today that it has completed the sale of its 15% shareholding in Malaysia LNG Tiga Sdn Bhd (MLNG Tiga) to the Sarawak State Financial Secretary (SFS) for an agreed consideration of $750 million.
RDS.B RDS.A RYDBF RDSB RDSA RYDAF

21
Shell sells equity in Malaysia LNG Tiga for $750 million

17h worldoil
KUALA LUMPUR -- Shell completes Malaysia LNG Tiga equity sale Shell Gas Holdings (Malaysia) Limited, a subsidiary of Royal Dutch Shell plc, announced today that it has completed the sale of its 15% shareholding in Malaysia LNG Tiga Sdn Bhd (MLNG Tiga) to the Sarawak State Financial Secretary (SFS) for an agreed consideration of $750 million.
RDS.B RDS.A RYDBF RDSB RDSA RYDAF

21
Climate Czar Tells OPEC to Pivot from Oil or Prepare to Suffer

17h rigzone
(Bloomberg) -- The world’s biggest crude exporters need to support the transition away from oil or prepare for growing climate-induced destabilization that could wreck their markets, the United Nation’s top environment official said.
FP RDS.B RDS.A RYDBF RDSB RDSA RYDAF

21
OPEC Told by Climate Czar to Pivot From Oil or Prepare to Suffer

17h rigzone
(Bloomberg) -- The world’s biggest crude exporters need to support the transition away from oil or prepare for growing climate-induced destabilization that could wreck their markets, the United Nation’s top environment official said.
FP RDS.B RDS.A RYDBF RDSB RDSA RYDAF

89
Top Analyst Reports for Schlumberger, Walgreens Boots & BNY Mellon

18h zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Schlumberger (SLB), Walgreens Boots (WBA) and BNY Mellon (BK). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
HD DUKH SLB GIS RDS.B RDS.A DUK RDSB RDSA SPG.PRJ SYK RYDBF ACN CSX SPG SLB RYDAF

21
Climate Czar Tells OPEC to Pivot From Oil or Prepare to Suffer - Bloomberg

18h bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
FP RDS.B RDS.A RYDBF RDSB RDSA RYDAF

21
Shell Sells $1.3B Of Oil And Gas Assets In Norway, Malaysia

19h rigzone
LONDON/ OSLO, June 20 (Reuters) - Royal Dutch Shell announced the sale on Wednesday of oil and gas assets in Norway and Malaysia for over $1.3 billion, bringing it closer to a target of $30 billion in disposals by year-end.
BRGXF BG BRGYY RDS.B RDS.A RYDBF RDSB RDSA RYDAF

21
Shell sells a further $1.3bn in oil assets

20h telegraph.co.uk
Royal Dutch Shell has pruned more than a billion dollars from its global oil portfolio by selling off assets in Norway and Malaysia.
RDS.B RDS.A RYDBF RDSB RDSA RYDAF

21
Shell sells Draugen, Gjøa interest in Norway

21h worldoil
THE HAGUE -- Royal Dutch Shell plc, through its affiliate A/S Norske Shell, has reached an agreement with OKEA AS to sell its entire 44.56% interest in Draugen and 12.00% interest in Gjøa in Norway for $556 million (NOK 4,520 million).
RDS.B RDS.A RYDBF RDSB RDSA RYDAF

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...